Terug
53
61
Dagbereik
€ 21,67
€ 22,15
52-Weeksbereik
€ 16,52
€ 25,15
Volume
831.721
50D / 200D Gem.
€ 21,55
/
€ 20,16
Vorige Slotkoers
€ 21,70
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 5,2 | 0,4 |
| P/B | 1,2 | 2,9 |
| ROE % | 29,1 | 3,7 |
| Net Margin % | 63,8 | 3,8 |
| Rev Growth 5Y % | 2,1 | 10,0 |
| D/E | 0,2 | 0,2 |
Belangrijkste Punten
Revenue grew 2,06% annually over 5 years — modest growth
Earnings grew 1059,22% over the past year
ROE of 29,09% indicates high profitability
Net margin of 63,78% shows strong profitability
Debt/Equity of 0,23 — conservative balance sheet
Generating 195,80M in free cash flow
Groei
Revenue Growth (5Y)
2,06%
Revenue (1Y)18,52%
Earnings (1Y)1059,22%
FCF Growth (3Y)17,99%
Kwaliteit
Return on Equity
29,09%
ROIC8,52%
Net Margin63,78%
Op. Margin38,52%
Veiligheid
Debt / Equity
0,23
Current Ratio14,64
Interest Coverage9,81
Waardering
P/E Ratio
5,20
P/B Ratio1,20
EV/EBITDA6,89
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 18,52% | Revenue Growth (3Y) | 17,02% |
| Earnings Growth (1Y) | 1059,22% | Earnings Growth (3Y) | 22,83% |
| Revenue Growth (5Y) | 2,06% | Earnings Growth (5Y) | 0,50% |
| Profitability | |||
| Revenue (TTM) | 425,13M | Net Income (TTM) | 271,17M |
| ROE | 29,09% | ROA | 16,58% |
| Gross Margin | 72,33% | Operating Margin | 38,52% |
| Net Margin | 63,78% | Free Cash Flow (TTM) | 195,80M |
| ROIC | 8,52% | FCF Growth (3Y) | 17,99% |
| Safety | |||
| Debt / Equity | 0,23 | Current Ratio | 14,64 |
| Interest Coverage | 9,81 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 5,20 | P/B Ratio | 1,20 |
| P/S Ratio | 3,32 | PEG Ratio | 0,01 |
| EV/EBITDA | 6,89 | Dividend Yield | 0,00% |
| Market Cap | 1,41B | Enterprise Value | 1,13B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 425,13M | 358,71M | 310,46M | 331,34M | 391,87M |
| Net Income | 271,17M | 23,39M | 179,72M | 213,92M | 265,85M |
| EPS (Diluted) | 3,30 | 0,36 | 2,20 | 2,37 | 2,87 |
| Gross Profit | 307,52M | 322,11M | 267,82M | 317,55M | 391,87M |
| Operating Income | 163,75M | 166,87M | 113,89M | -36,95M | 375,10M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1,64B | 1,30B | 1,24B | 1,23B | 926,40M |
| Total Liabilities | 462,32M | 609,90M | 568,55M | 665,71M | 400,46M |
| Shareholders' Equity | 1,17B | 691,16M | 674,96M | 565,79M | 414,74M |
| Total Debt | 269,02M | 451,10M | 449,08M | 544,07M | 394,76M |
| Cash & Equivalents | 550,94M | 304,96M | 193,51M | 291,05M | 201,53M |
| Current Assets | 727,52M | 554,31M | 344,22M | 443,51M | 313,67M |
| Current Liabilities | 49,70M | 236,08M | 38,13M | 134,97M | 5,81M |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Capital Light Compounder
#46 of 213
#84 of 658
Recente Activiteit
Ingestapt
Capital Light Compounder
Mar 24, 2026
Ingestapt
Contrarian Investing (David Dreman)
Mar 24, 2026